Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Conditions
Interventions
PRT543
Locations
23
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
UCSF Precision Cancer Medicine Building
San Francisco, California, United States
Christiana Care Health Services, Christiana Hospital
Newark, Delaware, United States
Florida Cancer Specialists
Lake Mary, Florida, United States
Florida Cancer Specialist
Sarasota, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
February 11, 2019
Primary Completion Date
November 16, 2022
Completion Date
November 16, 2022
Last Updated
March 28, 2023
Lead Sponsor
Prelude Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions